470 related articles for article (PubMed ID: 15837258)
1. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
[TBL] [Abstract][Full Text] [Related]
2. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.
Sherrid MV; Shetty A; Winson G; Kim B; Musat D; Alviar CL; Homel P; Balaram SK; Swistel DG
Circ Heart Fail; 2013 Jul; 6(4):694-702. PubMed ID: 23704138
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
[TBL] [Abstract][Full Text] [Related]
4. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
6. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment.
Musat D; Sherrid MV
Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():9-17. PubMed ID: 17162264
[TBL] [Abstract][Full Text] [Related]
8. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
9. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
[TBL] [Abstract][Full Text] [Related]
10. Does myectomy convey survival benefit in hypertrophic cardiomyopathy?
Woo A; Rakowski H
Heart Fail Clin; 2007 Jul; 3(3):275-88. PubMed ID: 17723936
[TBL] [Abstract][Full Text] [Related]
11. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.
Shah JS; Esteban MT; Thaman R; Sharma R; Mist B; Pantazis A; Ward D; Kohli SK; Page SP; Demetrescu C; Sevdalis E; Keren A; Pellerin D; McKenna WJ; Elliott PM
Heart; 2008 Oct; 94(10):1288-94. PubMed ID: 18032461
[TBL] [Abstract][Full Text] [Related]
13. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
[TBL] [Abstract][Full Text] [Related]
14. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy.
Nagueh SF; Buergler JM; Quinones MA; Spencer WH; Lawrie GM
J Am Coll Cardiol; 2007 Aug; 50(8):795-8. PubMed ID: 17707185
[TBL] [Abstract][Full Text] [Related]
15. Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?
Musat D; Marineci S; Sherrid MV
Prog Cardiovasc Dis; 2012; 54(6):535-42. PubMed ID: 22687597
[TBL] [Abstract][Full Text] [Related]
16. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy.
Woo A; Williams WG; Choi R; Wigle ED; Rozenblyum E; Fedwick K; Siu S; Ralph-Edwards A; Rakowski H
Circulation; 2005 Apr; 111(16):2033-41. PubMed ID: 15824202
[TBL] [Abstract][Full Text] [Related]
17. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
18. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
Sherrid MV; Arabadjian M
Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.
Ostman-Smith I
Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015
[TBL] [Abstract][Full Text] [Related]
20. Advances in medical treatment of hypertrophic cardiomyopathy.
Hamada M; Ikeda S; Shigematsu Y
J Cardiol; 2014 Jul; 64(1):1-10. PubMed ID: 24735741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
